Study characteristics.
| Characteristics | (41 studies, 1918 patients) |
| Range of publication year | 1989–2021 |
| Median (IQR) no of patients | 11 (5–29) |
| Geographical region | |
| North America | 19 (46) |
| Europe | 14 (34) |
| Central/South America | 0 (0) |
| Asia | 4 (10) |
| Other | 4 (10) |
| Study design | |
| Randomised trial | 1 (2) |
| Cohort | 19 (46) |
| Case-control | 2 (5) |
| Case-series | 19 (46) |
| Case definition | |
| Probable STSS patients | 115 (6) |
| Confirmed STSS patients | 227 (12) |
| Prognostic factor type | |
| Demographic | 29 (71) |
| Medical history | 5 (12) |
| Early disease | 11 (27) |
| Treatment | 16 (39) |
Values are numbers (percentages) of studies unless stated otherwise. Medical history included prognostic variable: immunocompromised. Early disease included prognostic variables: necrotising fasciitis, acute renal failure.
STSS, streptococcal toxic shock syndrome.